Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cash-Strong Vical Narrows Focus To Two Lead Programs

This article was originally published in The Pink Sheet Daily

Executive Summary

Wary of current financial environment, biotech is bullish on early pipeline projects but will await partners to advance them.

You may also be interested in...



Vical Joins Forces With Astellas On CMV Vaccine

Vaccine-focused biotech Vical Inc. announced July 14 that it has inked a global licensing agreement with Japan's Astellas Pharma Inc. to develop and commercialize the biotech's cytomegalovirus (CMV) vaccine, TransVax

Vical Joins Forces With Astellas On CMV Vaccine

Astellas will take over the development of TransVax and pay Vical $103 million plus royalties.

Vical Joins Forces With Astellas On CMV Vaccine

Astellas will take over the development of TransVax and pay Vical $103 million plus royalties.

Related Content

Topics

UsernamePublicRestriction

Register

PS067191

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel